Euroasian journal of hepato-gastroenterology

Register      Login

Table of Content

2022 | July-December | Volume 12 | Issue 2

Total Views


Satyam Satyam, Snehal Kose, Sapna Singh, Anjali Prakash, Anju Garg

Multidetector Computed Tomography Angiography Role in Diagnosing Superior Mesenteric Arteriovenous Fistula with Superior Mesenteric Vein Thrombosis: A Case Report

[Year:2022] [Month:July-December] [Volume:12] [Number:2] [Pages:4] [Pages No:98 - 101]

Keywords: Computed tomography angiography, Superior artery mesenteric vein thrombosis, Superior mesenteric arteriovenous fistula

   DOI: 10.5005/jp-journals-10018-1380  |  Open Access |  How to cite  | 


Introduction: Arteriovenous fistulas (AVF) of the superior mesenteric vasculature are rare vascular abnormalities. It often occurs due to iatrogenic injuries during bowel resection or abdominal traumas. As the patient exhibits a variety of signs and symptoms and can present late, diagnosis may be difficult. Multidetector computed tomography (MDCT) is the most common modality for imaging the small bowel, vessels, and mesentery in patients with mesenteric ischemia. Case presentation: We present the case of a 25-year-old man who presented with features of acute intestinal obstruction and was operated on in an emergency. Resection of gangrenous small bowel and bowel adhesiolysis with double barrel ileostomy was performed. During exploratory laparotomy, gangrenous bowels were found, but no cause of mesenteric ischemia could be delineated. Finally, on computed tomography angiography (CTA) superior mesenteric arteriovenous fistula (SMAVF) with superior mesenteric vein (SMV) thrombosis was diagnosed. The patient was advised of aggressive anticoagulant therapy. Conclusion: Computed tomography angiography has become the most reliable diagnostic modality to confirm the diagnosis and guide the best treatment strategy.



Himani Narula Khanna, Sushovan Roy, Aqsa Shaikh, Viswanath Bandi

Emerging Role and Place of Probiotics in the Management of Pediatric Neurodevelopmental Disorders

[Year:2022] [Month:July-December] [Volume:12] [Number:2] [Pages:7] [Pages No:102 - 108]

Keywords: Dysbiosis, Gut-brain axis, Neurodevelopmental disorders, Psychobiotics

   DOI: 10.5005/jp-journals-10018-1384  |  Open Access |  How to cite  | 


The current decade has witnessed significant developments with the latest therapeutic agents for managing various infectious diseases to complex hemato-oncological conditions, leading to a decrease in morbidity and mortality, while improving the quality of life (QoL), and increasing the life span. Non-communicable diseases (NCDs), which are on the rise across all age-groups, are being driven by unhealthy lifestyles and improved mental health issues. The current therapeutic agents were found to offer only symptomatic relief of varying efficacy and significant adverse effects, leading clinicians to evaluate other options for the management of both neurodevelopmental and neurodegenerative disorders. The role of gut microbiota has emerged as a potential target for the treatment of both neurodegenerative diseases and neurodevelopmental disorders like attention-deficit hyperactivity disorder (ADHD)/autism spectrum disorders (ASD) as a result of the decoding of the human genome and advances in our understanding of the human gut microbiome, including its interactions with the human brain. This review has been undertaken to understand on date level of understanding of human microbiota and towards identifying probiotic strains with proven efficacy and safety. According to recent investigations, several lactobacillus strains, including L. Paracasei 37, L. Planetarium 128, L. reuteri DSM 17938, and Bifidobacterium longum, have been effective in treating children's neurodevelopmental disorders such as ASD and ADHD. Future clinical studies are nonetheless required to confirm the long-term safety and effectiveness of probiotic strains in managing the primary and comorbid symptoms, hence improving patient and family quality of life.


© Jaypee Brothers Medical Publishers (P) LTD.